Rainer Hofmann
Research Subjects
Rainer Hofmann has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Axel Hegele
Department of Urology and Pediatric Urology, University Medical Center Marburg, Marburg, Germany
5 shared publications Peter Barth
3 shared publications- Peter Jochen Olbert
Universitätsklinikum Giessen und Marburg GmbH, Standort Marburg
2 shared publications - Peter Olbert
Urologie, Brixsana private clinic, Brixen, Italy
2 shared publications Peter Rexin
Institute of pathology, Phlipps University, Marburg, Germany
2 shared publicationsZoltan Varga
2 shared publications
Latest Publications
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16561
Correlation of RNA levels of certain members of the semaphorin/plexin/neuropilin family with the oncogenic ERG transcription factor in prostate cancer homogenate.
E16561 Background: Innervation of prostate cancer tissue by autonomic nerves impacts tumor progression and metastasis. Semaphorins (SEMAs) and their receptors namely plexins (PLXNs) and neuropilins (NRPs) affect cell motility, migration and metastasis with possible impact on tumor innervation. The gene fusion TMPRSS2-ERG occurs with a frequency of about 50% in prostate cancer resulting in enhanced androgen-dependent induction of the oncogenic transcription factor ERG. Here, we analyzed the expression levels of certain semaphorins and their receptors in relation to ERG in prostate cancer patients. Methods: We investigated a prostate cancer cohort that underwent radical prostatectomy for treatment. RNA obtained from paraffin embedded prostate cancer tissue was analyzed for gene fusion status, for levels of ERG and for several semaphorins, plexins and neuropilins by relative quantitative RT-PCR. Examinations were approved by the local Ethical Review Board (AZ 65/11). Results: We observed significant positive correlations of RNA levels of ERG with NRP2 (p < 0.05, n = 52), with PLXNA2 (p < 0.001, n = 77), PLXNB1 (p < 0.01, n = 78) and with SEMA4B (p < 0.01, n = 78). Conclusions: We suggest that NRP2, PLXNA2, PLXNB1, and SEMA4B may be at least partially under the control of ERG. Future studies will focus on a functional link of these components with metastasis and prostate cancer innervation.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16561
Correlation of RNA levels of certain members of the semaphorin/plexin/neuropilin family with the oncogenic ERG transcription factor in prostate cancer homogenate.
E16561 Background: Innervation of prostate cancer tissue by autonomic nerves impacts tumor progression and metastasis. Semaphorins (SEMAs) and their receptors namely plexins (PLXNs) and neuropilins (NRPs) affect cell motility, migration and metastasis with possible impact on tumor innervation. The gene fusion TMPRSS2-ERG occurs with a frequency of about 50% in prostate cancer resulting in enhanced androgen-dependent induction of the oncogenic transcription factor ERG. Here, we analyzed the expression levels of certain semaphorins and their receptors in relation to ERG in prostate cancer patients. Methods: We investigated a prostate cancer cohort that underwent radical prostatectomy for treatment. RNA obtained from paraffin embedded prostate cancer tissue was analyzed for gene fusion status, for levels of ERG and for several semaphorins, plexins and neuropilins by relative quantitative RT-PCR. Examinations were approved by the local Ethical Review Board (AZ 65/11). Results: We observed significant positive correlations of RNA levels of ERG with NRP2 (p < 0.05, n = 52), with PLXNA2 (p < 0.001, n = 77), PLXNB1 (p < 0.01, n = 78) and with SEMA4B (p < 0.01, n = 78). Conclusions: We suggest that NRP2, PLXNA2, PLXNB1, and SEMA4B may be at least partially under the control of ERG. Future studies will focus on a functional link of these components with metastasis and prostate cancer innervation.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16128
Changes of PD-1 expressing tumor infiltrating lymphocytes (TILs) in primary and metastatic tumor in renal cell carcinoma (RCC).
E16128 Background: Immune checkpoint inhibitors represent a new therapeutic option in metastatic RCC (mRCC) dependent on PD-1 and PD-L1 expression. We examined the occurrence and amount of PD-1 expressing tumor infiltrating lymphocytes (TILs)in the primary tumor (kidney) as well as in synchronous/metachronous metastases of RCC. Aim of this study was to detect possible correlations for development of metastases as well as differences in PD-1 expression level between primary and metastatic RCC. Methods: IHC was performed on paraffin embedded samples from patients with localised and metastasized RCC treated at the university hospital of Marburg (2013-2014) using an antibody against PD1 (Zytomed, Cat. No. 516-18662). Samples were scored as positive if any staining was seen (Level 0/1/2). Data were analyzed using SPSS for Windows (Version 22). Examinations were approved by the local Ethical Review Board (AZ 181/13). Results: PD-1 - expressing tumor infiltrating lymphocytes (TILs) were determined in kidney RCC samples of 43 patients: n = 6 no expression, n = 25 low level expression, n = 12 high level expression. We found no correlation of the level of PD – 1 positive TILs with T-stage (0.71), tumor differentiation (0.12) and concomitance of metastases (n = 5, 0.78). During follow-up 19 patients developed RCC metastases. The PD – 1 expression level comparing metastases with primary tumor was identical in 7 patients, lower in 3 patients and higher in 9 patients without significant correlation in this small cohort (0.86). We found also no correlation to PD-1 expression level in primary tumor site and development of metastases. Conclusions: The level of PD-1 expressing tumor infiltrating lymphocytes in localized RCC shows no correlation to clinical parameters. In addition PD-1 expression level in primary tumour and metastases changed in 63% (16 % decrease and 47% increase) of our patients illustrating possible variations in biological behaviour of metastases compared to primary tumor.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16128
Changes of PD-1 expressing tumor infiltrating lymphocytes (TILs) in primary and metastatic tumor in renal cell carcinoma (RCC).
E16128 Background: Immune checkpoint inhibitors represent a new therapeutic option in metastatic RCC (mRCC) dependent on PD-1 and PD-L1 expression. We examined the occurrence and amount of PD-1 expressing tumor infiltrating lymphocytes (TILs)in the primary tumor (kidney) as well as in synchronous/metachronous metastases of RCC. Aim of this study was to detect possible correlations for development of metastases as well as differences in PD-1 expression level between primary and metastatic RCC. Methods: IHC was performed on paraffin embedded samples from patients with localised and metastasized RCC treated at the university hospital of Marburg (2013-2014) using an antibody against PD1 (Zytomed, Cat. No. 516-18662). Samples were scored as positive if any staining was seen (Level 0/1/2). Data were analyzed using SPSS for Windows (Version 22). Examinations were approved by the local Ethical Review Board (AZ 181/13). Results: PD-1 - expressing tumor infiltrating lymphocytes (TILs) were determined in kidney RCC samples of 43 patients: n = 6 no expression, n = 25 low level expression, n = 12 high level expression. We found no correlation of the level of PD – 1 positive TILs with T-stage (0.71), tumor differentiation (0.12) and concomitance of metastases (n = 5, 0.78). During follow-up 19 patients developed RCC metastases. The PD – 1 expression level comparing metastases with primary tumor was identical in 7 patients, lower in 3 patients and higher in 9 patients without significant correlation in this small cohort (0.86). We found also no correlation to PD-1 expression level in primary tumor site and development of metastases. Conclusions: The level of PD-1 expressing tumor infiltrating lymphocytes in localized RCC shows no correlation to clinical parameters. In addition PD-1 expression level in primary tumour and metastases changed in 63% (16 % decrease and 47% increase) of our patients illustrating possible variations in biological behaviour of metastases compared to primary tumor.
- 1 December 2010
- Vol. 30 (12) , 5195-200
CA19.9 and CEA in transitional cell carcinoma of the bladder: serological and immunohistochemical findings.
Reliable blood and urine markers for transitional cell carcinoma of the bladder (TCC) do not currently exist. The aim of this prospective study was the serological and immunohistochemical evaluation of CA19.9 and CEA in TCC and to assess the correlation with different TCC stages. CA19.9 and CEA levels were prospectively determined in samples from 231 patients with TCC suspected bladder lesions, before transurethral tumor resection. Additionally, these serum parameters were determined in 11 patients with initial metastatic TCC. Immunohistochemical analysis on CA19.9 and CEA was performed in 83 patients. Neither CA19.9 nor CEA levels were significantly elevated in TCC patients. Patients with muscle-invasive TCC showed significantly higher levels of CEA (p = 0.008) and CA19.9 (p<0.001) compared to those with superficial TCC. Significantly higher levels were also evident with increasing grade of malignancy. Metastatic TCC showed significantly elevated CA19.9 levels compared to muscle invasive TCC as well as locally advanced (pT3/pT4/pN+) compared to localized TCC (pT2/pN0). Immunohistochemical staining revealed a strong correlation between CA19.9 serum levels and staining intensity. CEA and CA19.9 are not useful markers in primary diagnosis of TCC. However, in instances of elevated CEA and CA19.9 levels where gastrointestinal malignancy has been excluded, evidence of TCC should be sought. If elevated CEA and CA19.9 are present in TCC, serum levels correlate with tumor invasion and grade of malignancy.
- 1 December 2010
- Vol. 30 (12) , 5195-200
CA19.9 and CEA in transitional cell carcinoma of the bladder: serological and immunohistochemical findings.
Reliable blood and urine markers for transitional cell carcinoma of the bladder (TCC) do not currently exist. The aim of this prospective study was the serological and immunohistochemical evaluation of CA19.9 and CEA in TCC and to assess the correlation with different TCC stages. CA19.9 and CEA levels were prospectively determined in samples from 231 patients with TCC suspected bladder lesions, before transurethral tumor resection. Additionally, these serum parameters were determined in 11 patients with initial metastatic TCC. Immunohistochemical analysis on CA19.9 and CEA was performed in 83 patients. Neither CA19.9 nor CEA levels were significantly elevated in TCC patients. Patients with muscle-invasive TCC showed significantly higher levels of CEA (p = 0.008) and CA19.9 (p<0.001) compared to those with superficial TCC. Significantly higher levels were also evident with increasing grade of malignancy. Metastatic TCC showed significantly elevated CA19.9 levels compared to muscle invasive TCC as well as locally advanced (pT3/pT4/pN+) compared to localized TCC (pT2/pN0). Immunohistochemical staining revealed a strong correlation between CA19.9 serum levels and staining intensity. CEA and CA19.9 are not useful markers in primary diagnosis of TCC. However, in instances of elevated CEA and CA19.9 levels where gastrointestinal malignancy has been excluded, evidence of TCC should be sought. If elevated CEA and CA19.9 are present in TCC, serum levels correlate with tumor invasion and grade of malignancy.
- 1 June 2009
- Vol. 29 (6) , 2067-76
In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Intravesical BCG instillation is established and efficient in the prophylaxis of recurrent transitional cell carcinoma. A Th-1 biased immune response is postulated. Recent work has proven the efficacy of synthetic CpG-Oligodeoxynucleotides (ODN) as inducers and adjuvants for a strong Th1-response and there is evidence for a direct and/or adjuvant anti-neoplastic effect. The purpose of this study was to examine the local effects of CpG-ODN on the murine bladder wall after intravesical instillation and the effects on cytokine expression in an orthotopic murine bladder cancer model. Histopathology, immunohistochemistry and fluorescence microscopy were performed after different instillation schedules of stimulatory, non-stimulatory biotinylized and FITC-labelled CpG-ODN into the murine bladder. MB-49 murine bladder cancer cells were tested for TLR-9 expression to exclude a potential direct responsiveness to CpG-ODN. Furthermore induction of apoptosis was tested by annexin V staining and FACS analysis of CpG-ODN stimulated tumor cells. In an orthotopic C57/Bl6 murine bladder cancer model, the expressions of IL-12, IFNgamma, IL-10 and TGF-beta were evaluated after repeated CpG-ODN treatment. Single and repeated instillation of CpG-ODN induced subepithelial and urothelial lymphocytic infiltrations with consecutive apoptoses. PBS and non-stimulative ODN induced no visible reaction. Bladder submucosa stained positive for biotin. Controls showed no endogenic biotin staining. FITC-labelled ODN adhered to the bladder mucosa and penetration of the mucosal barrier was not detected. MB-49 TCC cells did not express TLR-9 and CpG-ODN did not induce apoptosis in these cells. Repeated intravesical instillations of CpG-ODN in orthotopic murine tumor bearing urinary bladders resulted in significant up-regulation of both Th-1 and Th-2 cytokines. CpG-ODNs have promising anti-neoplastic potential. They exert a pronounced immunological response both in the native murine urinary bladder and in murine TCC. The mechanisms of action appear to be mediated immunologically, There was no direct effect of CpG-ODN on the tumor cells in this model.
- 1 June 2009
- Vol. 29 (6) , 2067-76
In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Intravesical BCG instillation is established and efficient in the prophylaxis of recurrent transitional cell carcinoma. A Th-1 biased immune response is postulated. Recent work has proven the efficacy of synthetic CpG-Oligodeoxynucleotides (ODN) as inducers and adjuvants for a strong Th1-response and there is evidence for a direct and/or adjuvant anti-neoplastic effect. The purpose of this study was to examine the local effects of CpG-ODN on the murine bladder wall after intravesical instillation and the effects on cytokine expression in an orthotopic murine bladder cancer model. Histopathology, immunohistochemistry and fluorescence microscopy were performed after different instillation schedules of stimulatory, non-stimulatory biotinylized and FITC-labelled CpG-ODN into the murine bladder. MB-49 murine bladder cancer cells were tested for TLR-9 expression to exclude a potential direct responsiveness to CpG-ODN. Furthermore induction of apoptosis was tested by annexin V staining and FACS analysis of CpG-ODN stimulated tumor cells. In an orthotopic C57/Bl6 murine bladder cancer model, the expressions of IL-12, IFNgamma, IL-10 and TGF-beta were evaluated after repeated CpG-ODN treatment. Single and repeated instillation of CpG-ODN induced subepithelial and urothelial lymphocytic infiltrations with consecutive apoptoses. PBS and non-stimulative ODN induced no visible reaction. Bladder submucosa stained positive for biotin. Controls showed no endogenic biotin staining. FITC-labelled ODN adhered to the bladder mucosa and penetration of the mucosal barrier was not detected. MB-49 TCC cells did not express TLR-9 and CpG-ODN did not induce apoptosis in these cells. Repeated intravesical instillations of CpG-ODN in orthotopic murine tumor bearing urinary bladders resulted in significant up-regulation of both Th-1 and Th-2 cytokines. CpG-ODNs have promising anti-neoplastic potential. They exert a pronounced immunological response both in the native murine urinary bladder and in murine TCC. The mechanisms of action appear to be mediated immunologically, There was no direct effect of CpG-ODN on the tumor cells in this model.
- 1 May 2006
- Published by Springer Nature in Der Urologe
- Vol. 45 (5) , 637-647
Ureterorenoskopie (URS) bei Harnsteinen
- 1 May 2006
- Published by Springer Nature in Der Urologe
- Vol. 45 (5) , 637-647
Ureterorenoskopie (URS) bei Harnsteinen
- 28 August 2004
- Vol. 24 (4) , 2225-30
Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.
Intravesical BCG installation is the standard of care in the prophylaxis of recurrent intermediate and high-risk transitional cell carcinoma (TCC), but its mode of action has not yet been elucidated. However, a Th-1 biased immune response is postulated Cell culture and animal models demonstrated the efficacy of synthetic CpG-oligodeoxynucleotides (ODN) as inducer and adjuvant for a strong Th1-response. The purpose of our study was to evaluate the antineoplastic effect of locally administered CpG ODN in a subcutaneous murine bladder cancer model. A subcutaneous murine TCC model was established in female C57/BL6 mice using the corresponding syngeneic MB49 TCC cell line. Three groups of 5 animals received a cell suspension, standardized for 1x10(6) cells/50 microl, injected s.c. into the right and left flank. Group I received 10 nmol of CpG-ODN only into the right cell depot. Group II received 10 nmol of GpC ODN. Group III served as untreated control and received only PBS. The animals were examined at various time points after injection until sacrifice on day 14. Tumor or scar tissue were excised, weighed and examined histopathologically (HE-stain). Tumor sizes and weights showed no side differences. The average tumor weight on day 14 was 171 mg (SD +/- 8.9), 110 mg (SD +/- 19.2) and 18 mg (SD +/- 6.1), respectively, in groups III, II and I (p<0.05). Histopathology revealed solid vital epithelial tumors in group III and reduced vital tumor mass with central necrosis and moderate mononuclear infiltration in group II. Group I showed almost complete tumor necrosis and a considerable mononuclear inflammatory response. Immunostimulatory DNA has promising antineoplastic activity in a murine subcutaneous TCC-model. The histological findings suggest an immunologically-mediated mode of action. Further investigations are necessary to elucidate the immunological response.
- 28 August 2004
- Vol. 24 (4) , 2225-30
Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.
Intravesical BCG installation is the standard of care in the prophylaxis of recurrent intermediate and high-risk transitional cell carcinoma (TCC), but its mode of action has not yet been elucidated. However, a Th-1 biased immune response is postulated Cell culture and animal models demonstrated the efficacy of synthetic CpG-oligodeoxynucleotides (ODN) as inducer and adjuvant for a strong Th1-response. The purpose of our study was to evaluate the antineoplastic effect of locally administered CpG ODN in a subcutaneous murine bladder cancer model. A subcutaneous murine TCC model was established in female C57/BL6 mice using the corresponding syngeneic MB49 TCC cell line. Three groups of 5 animals received a cell suspension, standardized for 1x10(6) cells/50 microl, injected s.c. into the right and left flank. Group I received 10 nmol of CpG-ODN only into the right cell depot. Group II received 10 nmol of GpC ODN. Group III served as untreated control and received only PBS. The animals were examined at various time points after injection until sacrifice on day 14. Tumor or scar tissue were excised, weighed and examined histopathologically (HE-stain). Tumor sizes and weights showed no side differences. The average tumor weight on day 14 was 171 mg (SD +/- 8.9), 110 mg (SD +/- 19.2) and 18 mg (SD +/- 6.1), respectively, in groups III, II and I (p<0.05). Histopathology revealed solid vital epithelial tumors in group III and reduced vital tumor mass with central necrosis and moderate mononuclear infiltration in group II. Group I showed almost complete tumor necrosis and a considerable mononuclear inflammatory response. Immunostimulatory DNA has promising antineoplastic activity in a murine subcutaneous TCC-model. The histological findings suggest an immunologically-mediated mode of action. Further investigations are necessary to elucidate the immunological response.
- 1 January 2004
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 171 (1) , 384-386
Fetoscopic Placement of a Transurethral Stent for Intrauterine Obstructive Uropathy
Fetal urinary obstructive uropathy and consecutive oligohydramnios result in a poor outcome. Usually renal insufficiency and life threatening lung hypoplasia have developed at term. We report a case of in utero fetal cystoscopy and successful placement of a transurethral vesico-amniotic Double-J (Medical Engineering Corp., New York, New York) stent. Indications, results and the potential benefits of different techniques are discussed. A 36-year-old woman (primipara) was evaluated at week 26 due to a male fetus with bilateral hydronephrosis, massive distended bladder and an open posterior urethra. Using local anesthesia the fetal bladder was punctured, a 2.6 mm endoscope was inserted and a wire was advanced antegrade through the penis. A 2.8Fr Double-J stent was then placed between the bladder and amniotic cavity. The bladder drained into the amnion, hydronephrosis disappeared and the lung developed normally. At week 37 a healthy infant was delivered who voided spontaneously. After careful selection of candidates for fetal intervention in obstructive uropathy direct vision fetoscopy and transurethral stent placement can be performed in patients with oligohydramnios, favorable urinary electrolytes and normal appearing kidneys.
- 1 January 2004
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 171 (1) , 384-386
Fetoscopic Placement of a Transurethral Stent for Intrauterine Obstructive Uropathy
Fetal urinary obstructive uropathy and consecutive oligohydramnios result in a poor outcome. Usually renal insufficiency and life threatening lung hypoplasia have developed at term. We report a case of in utero fetal cystoscopy and successful placement of a transurethral vesico-amniotic Double-J (Medical Engineering Corp., New York, New York) stent. Indications, results and the potential benefits of different techniques are discussed. A 36-year-old woman (primipara) was evaluated at week 26 due to a male fetus with bilateral hydronephrosis, massive distended bladder and an open posterior urethra. Using local anesthesia the fetal bladder was punctured, a 2.6 mm endoscope was inserted and a wire was advanced antegrade through the penis. A 2.8Fr Double-J stent was then placed between the bladder and amniotic cavity. The bladder drained into the amnion, hydronephrosis disappeared and the lung developed normally. At week 37 a healthy infant was delivered who voided spontaneously. After careful selection of candidates for fetal intervention in obstructive uropathy direct vision fetoscopy and transurethral stent placement can be performed in patients with oligohydramnios, favorable urinary electrolytes and normal appearing kidneys.